Business
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World's Premier Cancer Research Forum
VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Unveils Preclinical Data at the AACR - World’s Premier Cancer Research ForumCutting-Edge Research Results Showcase AI-Powered Drug Discovery\n\n\n\n VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced that two of its abstracts have been accepted for presentation at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30 in Chicago, Illinois.\n \n\n The AACR Annual Meeting is widely considered the most prestigious global forum for cancer research. It is where the world’s leading scientists, clinicians, and biotech innovators gather to unveil next-generation oncology breakthroughs. Rakovina’s acceptance to present, highlights growing recognition for its pioneering work at the intersection of AI technology and precision cancer therapy.\n \n\n\n AI-Designed Therapies Poised to Transform Cancer Treatment\n \n\n\n Rakovina will present two abstracts at the meeting, the first:\n \n Discovery of novel PARP1-selective inhibitors for treatment of brain tumors using artificial intelligence\n \n , explores the use of artificial intelligence (AI) to develop a novel, brain-penetrant, PARP1-selective inhibitor for treating brain tumors. Current PARP inhibitors face challenges such as poor blood-brain barrier (BBB) permeability and off-target effects due to PARP2 inhibition. By leveraging Deep Docking, a deep learning-based virtual screening method, alongside generative AI algorithms, researchers rapidly identified potential compounds with strong PARP1 selectivity and BBB penetration. The study presents findings from in silico screening of billions of compounds, followed by in vitro and in vivo validation of their efficacy, selectivity, and pharmacokinetic properties. This AI-driven approach enhances the efficiency of drug discovery, offering a promising new treatment option for brain tumors.\n \n\n The second abstract:\n \n Utilizing artificial intelligence for the discovery of a novel CNS-penetrating ATR inhibitor,\n \n highlights the use of artificial intelligence (AI) to develop a novel CNS-penetrating ATR inhibitor for treating brain tum...